The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

Name: The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.
Published: 2023
License: Public Domain

Fudan University · 2023

ClinicalTrials.gov · Datasets · License: Public Domain · 2023

Open Source ↗

homologous recombination deficiency alterations metastatic colorectal cancer, fluzoparib plus irinotecan, homologous recombination deficiency (hrd) alterations, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

Related documents